GlassScriptPhysician profile
Bradley H Crombie
NPI 1134118540
$3,926.80
in general payments reported to CMS, 2019-2025
42 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $195 · 2021: $505 · 2022: $413 · 2023: $771 · 2024: $391 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.01 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $453.43 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $259.20 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $215.74 | 2021-2025 | |
| Amarin Pharma, INC. | $206.81 | 2019-2020 | |
| Pfizer INC. | $198.52 | 2019-2024 | |
| Astellas Pharma US INC | $195.63 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $188.79 | 2019-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.53 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $149.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $137.87 | 2019-2024 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $109.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $81.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2022-2024 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $65.59 | 2023-2024 | Gvoke Hypopen |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Crombie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.